Journal of Clinical Virology - Volume 82 - Supplement 1 - September 2016

86 / 152

S82 Abstracts / Journal of Clinical Virology 82S (2016) S1–S142
and is usually associated with virus inactivation hought hep-
atitis B virus infection stages are serologically clearly defined the
interpretation of results is not always easy in practice. E.g. anti-HBc
indicates usually exposure to HBV, but found in daily practice pro-
file such as: ‘anti-HBc only’ may mean false positive result. It is very
important to give clinicians as accurate results as possible, so they
can assess diseases stage and apply appropriate treatment. Aim of
this study was to compare the results obtained with ADVIA Cen-
taur XP (Siemens Healthcare Diagnostics, USA) chemiluminescence
immunoassays, currently used to determine hepatitis B serologi-
cal markers in our lab, with the results obtained with two other
automated platforms: LIAISON® XL (DiaSorin, Saluggia, Italy) and
Elecsys Cobas (Roche Diagnostics, Switzerland).
Materials and methods: Serum samples (patient samples and
quality specimen – UK, NEQAS) have been tasted for the qualitative
or quantitative detection of 6 hepatitis B virus serological mark-
ers with assays from three chemiluminescent automated systems
mentioned above.
Results: The correlation between the tests performed on
LIAISON® XL and ADVIA Centaur XP (patient samples) was: 100%
for HBsAg, 96.7% for anti-HBs, 100% for anti-HBcIgM, 98.4% for
anti-HBc-t, 100% for HBeAg and 95.3% for anti-HBe. The correla-
tion between the tests performed on Elecsys and ADVIA Centaur XP
(patient samples) was: 98.2% for HBsAg, 95.8% for anti-HBs, 97.7%
for anti-HBcIgM, 94% for anti-HBc, 99% for HBeAg and 96.6% for
anti-HBe. Weak positive ‘anti-HBc only’ results by the ADVIA Cen-
taur anti-HBc assay were negative by both LIASON XL and Elecsys
Anti-HBc assay. Results for all quality specimen were the same by
all platforms.
Conclusion: All three systems demonstrated assays suitable for
routine use.
Reference
[1] D. Lavanchy, Hepatitis B virus epidemiology, disease burden, treatment, and
current and emerging prevention and control measures, J. Viral Hepat. 11 (2)
(2004) 97–107.
[2] N. Hansen, G. Hay, S. Cowan, P. Jepsen, H. Bygum Krarup, N. Obel, et al.,
Hepatitis B prevalence in Denmark – an estimate based on nationwide
registers and a national screening programme, as on 31 December 2007, Euro
Surveill. Bull. Eur. Sur. Mal. Transm. Eur. Commun. Dis. Bull. 18 (47) (2013).
[3] Diagnosís of hepatitis B virus infection, 2016.
Abstract no: 352
Presentation at ESCV 2016: Poster 123
Comparative study of DxN VERIS molecular
diagnostics system and the COBAS
AmpliPrep/COBAS TaqMan platform for the
determination of viral load in Hepatitis C virus
infected patients
J.M. Molina ∗, J. Córdoba, M.D. Gomez,
J.L. Hontangas
Hospital La Fe, Valencia, Spain
Introduction: The ability to measure the hepatitis C virus viral
load in HCV infected patients has been available for several years on
molecular diagnostics platforms from a number of manufacturer’s.
Among these systems the COBAS AmpliPrep/COBAS TaqManmanu-
factured by Roche Diagnostics is widely used. The Beckman Coulter
DxN VERIS system is a more recent addition to the list of platforms
available for such assays. This aim of this study was to compare
the performance of the DxN VERIS system with that of the Roche
system for the accurate determination of HCV viral load in HCV
infected patients.
Methods: A total of 71 plasma samples of patients entering our
laboratory with the request for HCV viral load and HCV genotyping
were collected. Samples were analyzed in parallel with the COBAS
AmpliPrep/COBAS TaqMan system and the DxN VERIS system. The
HCV genotype was determined using the VERSANT HCV Genotype
Assay Kit (LIPA) SIEMENS.
Results: Of the71 samples tested 18 were positive and overall
therewas a good correlation between the two techniques ( r= 0.963)
for the parameter studied. The majority of the samples were deter-
mined to be HCV genotype 1, specifically 1a and 1b (n = 13), while
three were un-typed. Other genotypes identified included HCV
genotype 4a/4c/4d ( n = 1) and 2a/2c (n = 1). Comparison of the VERIS
HCV assay and Roche HCV assay results for the HCV genotype 1
sample showed that there was a good correlation between meth-
ods. This was observed for both genotype 1a or 1b. However for
HCV genotype’s 2a/2c and 4a/4c/4d a difference was observed
between bothmethods (difference of −0.95 log cp/mL for 2a/2c and
−1.25 log cp/mL for 4a/4c/4d).
Conclusion: The results indicate that the HCV viral load results
generated on the DxN VERIS systemwere reproducible when com-
pared to the reference method (COBAS). This together with the
other features of the DxN VERIS systemmakes this device very use-
ful in the daily routine diagnosis and monitoring of HCV viral load.
The other features of the system include the ability to test samples
from primary tubes and a bi-directional interface linking the DxN
VERIS to the laboratory computer system (SIL). However, although
it seems a coincidence, we should consider whether HCV geno-
types 2 and 4 show discrepancies between the two techniques or
is it a chance. A statistically significant number of samples of these
genotypes should be tested to determine whether or not there is
a discrepancy between the two methods. If this is confirmed then
the cause should be determined.
Abstract no: 40
Presentation at ESCV 2016: Poster 124
Apolipoprotein(a) inhibits hepatitis C virus
entry
C. Oliveira ∗ . Fournier escamps
V. Morel , C.A. Scipione , M.L. Koschinsky ,
A. Boullier , P. Marcelo , J.M. Domon ,
E. Brochot , G. Duverlie , C. Francois ,
S. Castelain , F. Helle
1 EA4294, Laboratoire de Virologie, Centre
Universitaire de Recherche en Santé, Centre
Hospitalier Universitaire et Université de Picardie
Jules Verne, 80054 Amiens, France
2 Department of Chemistry & Biochemistry,
University of Windsor, Windsor, ON, Canada
3 INSERM U-1088, Université de Picardie Jules Verne,
Centre Hospitalier Universitaire Sud, 80054 Amiens,
France
4 Plateforme ICAP, Centre Universitaire de Recherche
en Santé, Université de Picardie Jules Verne, 80054
Amiens, France
5 EA3900 BIOPI, Biologie des Plantes et Innovation,
UFR des Sciences, Université de Picardie Jules Verne,
33 rue St Leu, 80039 Amiens, France
In the last two decades, the development of different cell-based
models has greatly contributed to improve the knowledge of HCV
life cycle. However, it is still impossible to grow primary HCV iso-
lates from each genotype in cell culture. This would open new